Geoffroy Liegeon1,2, Nicole Ngo-Giang-Huong2,3, Nicolas Salvadori2,3, Piyawan Bunpo4, Ratchada Cressey4, Jullapong Achalapong5, Prateep Kanjanavikai6, Orada Patamasingh Na Ayudhaya7, Sinart Prommas8, Thitiporn Siriwachirachai9, Prapan Sabsanong10, Jean Yves Mary11, Gonzague Jourdain2,3. 1. Department of Infectious Diseases, Hôpital Saint-Louis et Lariboisière, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France. 2. MIVEGEC, Université Montpellier, CNRS, IRD, Montpellier, France. 3. Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. 4. Division of Clinical Chemistry, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand. 5. Department of Obstetrics, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand. 6. Department of Obstetrics, Banglamung Hospital, Chonburi, Thailand. 7. Department of Obstetrics, Nopparat Rajathanee Hospital, Bangkok, Thailand. 8. Department of Obstetrics, Bhumibol Adulyadej Hospital, Bangkok, Thailand. 9. Department of Obstetrics, Khon Kaen Hospital, Khon Kaen, Thailand. 10. Department of Obstetrics, Samutsakhon Hospital, Samutsakhon, Thailand. 11. INSERM U1153, Team ECSTRA, Université Paris Diderot - Paris 7, Hôpital Saint-Louis, Paris, France.
Abstract
BACKGROUND: Data evaluating the risk of proximal tubular dysfunction in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission (PMTCT) of HBV are scarce. OBJECTIVES: To assess the risk of proximal tubulopathy in pregnant women receiving tenofovir disoproxil fumarate for PMTCT of HBV. PATIENTS AND METHODS: We used urine samples collected from HBV monoinfected pregnant women who participated in a Phase III, multicentre, randomized, double-blind, placebo-controlled clinical trial assessing a tenofovir disoproxil fumarate short course from 28 weeks gestational age (28-wk-GA) to 2 months post-partum (2-months-PP) for PMTCT of HBV in Thailand. Markers of tubular dysfunction, including retinol binding protein, kidney injury molecule-1, α1-microglobuin and β2-microglobulin, were assayed at 28- and 32-wk-GA and 2-months-PP visits. Proximal tubulopathy was defined as the presence of ≥2 of the following: tubular proteinuria, euglycaemic glycosuria and increased urinary phosphate. RESULTS: A total of 291 women participated in the study. No kidney-related adverse events were severe, and none led to tenofovir disoproxil fumarate discontinuation. At 2-months-PP, 3 of the 120 (3%) evaluated women in the tenofovir disoproxil fumarate group experienced proximal tubulopathy versus 3 of 125 (2%) in the placebo group (P = 1.00). None of the six women met the criteria for proximal tubulopathy at 12-months-PP but proteinuria persisted in three of them. No growth abnormalities were found at 1 year of age in infants born to mothers with proximal tubulopathy at 2-months-PP. CONCLUSIONS: In these HBV-infected pregnant and breastfeeding women, tenofovir disoproxil fumarate administered from 28-wk-GA to 2-months-PP was not associated with a higher risk of proximal tubulopathy.
BACKGROUND: Data evaluating the risk of proximal tubular dysfunction in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission (PMTCT) of HBV are scarce. OBJECTIVES: To assess the risk of proximal tubulopathy in pregnant women receiving tenofovir disoproxil fumarate for PMTCT of HBV. PATIENTS AND METHODS: We used urine samples collected from HBV monoinfected pregnant women who participated in a Phase III, multicentre, randomized, double-blind, placebo-controlled clinical trial assessing a tenofovir disoproxil fumarate short course from 28 weeks gestational age (28-wk-GA) to 2 months post-partum (2-months-PP) for PMTCT of HBV in Thailand. Markers of tubular dysfunction, including retinol binding protein, kidney injury molecule-1, α1-microglobuin and β2-microglobulin, were assayed at 28- and 32-wk-GA and 2-months-PP visits. Proximal tubulopathy was defined as the presence of ≥2 of the following: tubular proteinuria, euglycaemic glycosuria and increased urinary phosphate. RESULTS: A total of 291 women participated in the study. No kidney-related adverse events were severe, and none led to tenofovir disoproxil fumarate discontinuation. At 2-months-PP, 3 of the 120 (3%) evaluated women in the tenofovir disoproxil fumarate group experienced proximal tubulopathy versus 3 of 125 (2%) in the placebo group (P = 1.00). None of the six women met the criteria for proximal tubulopathy at 12-months-PP but proteinuria persisted in three of them. No growth abnormalities were found at 1 year of age in infants born to mothers with proximal tubulopathy at 2-months-PP. CONCLUSIONS: In these HBV-infected pregnant and breastfeeding women, tenofovir disoproxil fumarate administered from 28-wk-GA to 2-months-PP was not associated with a higher risk of proximal tubulopathy.
Authors: Nicolas Salvadori; Bo Fan; Waralee Teeyasoontranon; Nicole Ngo-Giang-Huong; Siriluk Phanomcheong; Anita Luvira; Achara Puangsombat; Arunrat Suwannarat; Ussanee Srirompotong; Chaiwat Putiyanun; Tim R Cressey; Luc Decker; Woottichai Khamduang; Linda Harrison; Camlin Tierney; John A Shepherd; Athena P Kourtis; Marc Bulterys; George K Siberry; Gonzague Jourdain Journal: Clin Infect Dis Date: 2019-06-18 Impact factor: 9.079
Authors: Sonia Rodríguez-Nóvoa; Javier García-Samaniego; Martín Prieto; José L Calleja; Juan M Pascasio; Manuel Delgado Blanco; Javier Crespo; María Buti; Maria L Bonet Vidal; Juan Arenas Ruiz Tapiador; Conrado Fernández-Rodríguez; Ricard Solá; Enrique Fraga; Luisa González Diéguez; Oscar Núñez; Manuel Praga; Javier Del Pino-Montes; Manuel Romero-Gómez; Rosa Morillas; Moisés Diago; Ángeles Castro Journal: J Clin Gastroenterol Date: 2016-10 Impact factor: 3.062
Authors: Rafael N Moresco; Guilherme V Bochi; Carolina S Stein; José A M De Carvalho; Bibiana M Cembranel; Yãnaí S Bollick Journal: Clin Chim Acta Date: 2018-09-07 Impact factor: 3.786